BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral ...

Retrieved on: 2022-09-10 18:28:22

Tags for this article:

Health

Articles

Pharmaceutical industry

Clinical research

Drug discovery

Design of experiments

Food and Drug Administration

Clinical trial

Medication

Drug development

Forward-looking statement

Phases of clinical research

BeiGene

Click the tags to see associated articles and topics

BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral .... View article details on HISWAI: https://markets.financialcontent.com/stocks/article/bizwire-2022-9-10-beigene-announces-data-presentations-at-esmo-2022-including-late-breaking-oral-presentation-for-tislelizumab-in-first-line-unresectable-hepatocellular-cancer

Excerpt

Tislelizumab is a humanized IgG4 anti-PD-1 monoclonal antibody ... anti-tumor activity of PD-1 antibodies through activation of antibody-dependent ...

Article found on: markets.financialcontent.com

View Original Article